Q RT-PCR detection of chromogranin A: A new standard in the identification of neuroendocrine tumor disease

Annals of Surgery

Volumn 243, Issue 2, 2006, Pages 273-280

  Kidd, Mark ^a   Modlin, Irvin M ^a   Mane, Shrikant M ^a   Camp, Robert L ^a   Shapiro, Michael D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; MESSENGER RNA;

ADOLESCENT; ADULT; AGED; APPENDIX TUMOR; ARTICLE; CELL SUBPOPULATION; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC TEST; EPITHELIUM TUMOR; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MICROMETASTASIS; MICROSCOPY; MORPHOLOGY; NEUROENDOCRINE TUMOR; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SMALL INTESTINE TUMOR; STOMACH ADENOCARCINOMA; STOMACH CARCINOID; TISSUE MICROARRAY;

ADOLESCENT; ADULT; AGED; CARCINOID TUMOR; CHI-SQUARE DISTRIBUTION; CHILD; CHROMOGRANIN A; CHROMOGRANINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 31844445844     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000197734.28551.0f     Document Type: Article

References (27)

1. Deftos LJ. Chromogranin A its role in endocrine function, and as an endocrine and neuroendocrine tumor marker. Endocr Rev. 1991;12:181-187.
2. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med. 1986;314:1145-1151.
3. Ardill JE, Erikkson B. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocr Relat Cancer. 2003;10:459-462.
4. Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion. 2000;62(suppl 1):33-38.
5. Sundaresan V, Reeve JG, Stenning S, et al. Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumors. Br J Cancer. 1991;64:333-338.
6. Scopsi L, Andreola S, Pilotti S, et al. Argyrophylia and granin (chromogranin/secretogranin) expression in female breast carcinomas: their relationship to survival and other disease parameters. Am J Surg Pathol. 1992;16:561-576.
7. di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate: diagnostic, prognostic and therapeutic implications. Cancer. 1992;70:254-268.
8. De Bruïne AP, Wiggers T, Beek C, et al. Endocrine cells in colorectal adenocarcinomas: incidence, hormone profile and prognostic relevance. Int J Cancer. 1993;54:765-771.
9. Pour PM, Permert J, Mogaki M, et al. Endocrine aspects of exocrine cancer of the pancreas: their patterns and suggested biologic significance. Am J Clin Pathol. 1993;100:223-230.
10. Tarle M, Frkovic-Grazio S, Kraljic I, et al. A more objective staging of advanced prostate cancer: routine recognition of malignant endocrine structures. The assessment of serum TPS, PSA, and NSE values. Prostate. 1994;24:143-148.
11. Kadmon D, Thompson TC, Lynch GR, et al. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 1991;146: 358-361.
12. Deftos LJ, Nakada S, Burton DW, et al. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology. 1996;48:58-62.
13. Sobol RE, O'Connor DT, Addison J, et al. Elevated serum chromogranin A concentrations in small-cell lung carcinoma. Ann Intern Med. 1986; 105:698-700.
14. Wu JT, Erickson AJ, Tsao KC, et al. Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages. Ann Clin Lab Sci. 2000;30:175-178.
15. Walch A, Specht K, Smida J, et al. Tissue microdissection techniques in quantitative genome and gene expression analyses. Histochem Cell Biol. 2001;115:269-276.
16. Xie W, Mertens J, Reiss D, et al. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res. 2002;62:497-505.
17. Kidd M, Eick G, Shapiro MD, et al. Microsatellite instability and gene mutations in TGFβRII are absent in small bowel carcinoid tumors. Cancer. 2005;103:229-236.
18. Camp R, Dolled-Filhart M, King B, et al. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of Her2 expression are associated with poor outcome. Cancer Res. 2003; 63:1445-1448.
19. Camp R, Chung G, Rimm D. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002;8:1323-1328.
20. Camp R, Charette L, Rimm D. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000;80:1943-1949.
21. Rindi G, Leiter AB, Kopin AS, et al. The 'normal' endocrine cell of the gut: changing concepts and new evidences. Ann NY Acad Sci. 2004; 1014:1-12.
22. Modlin IM, Lye K, Kidd M. Gastric carcinoid tumors. Surg Oncol. 2003;12:153-172.
23. Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab. 1997;82:2622-2628.
24. Granberg D, Wilander E, Stridsberg M, et al. Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. Gut. 1998;43:223-228.
25. Goede AC, Caplin ME, Winslet MC. Carcinoid tumour of the appendix. Br J Surg. 2003;90:1317-1322.
26. Bilchik AJ, Nora DT, Saha S, et al. The use of molecular profiling of early colorectal cancer to predict micrometastases. Arch Surg. 2002;137: 1377-1383.
27. Taback B, Bilchik AJ, Saha S, et al. Peptide nucleic acid clamp PCR: a novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes. Int J Cancer. 2004;111:409-414.